Wealth Enhancement Advisory Services
NMRA icon

Wealth Enhancement Advisory Services’s Neumora Therapeutics NMRA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.36K Buy
+11,176
New +$15.5K ﹤0.01% 4213
2025
Q4 		– Sell
-10,433
Closed -$19.4K – 3754
2025
Q3 		$19.4K Sell
10,433
-19,387
-65% -$31.3K ﹤0.01% 3512
2025
Q2 		$24.5K Buy
29,820
+13,862
+87% +$10.5K ﹤0.01% 3284
2025
Q1 		$16K Buy
+15,958
New +$27.3K ﹤0.01% 2925
2024
Q2 		– Sell
-12,576
Closed -$173K – 2675
2024
Q1 		$173K Buy
+12,576
New +$203K ﹤0.01% 2222

Other funds holding NMRA

LPT
Legacy Private Trust Neenah, Wisconsin $1.83B AUM 13% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Wealth Enhancement Advisory Services's NMRA Position: Q3 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Neumora Therapeutics (NMRA) in Q3 2026: 11,176 shares worth $5.36K. The stake represents ﹤0.01% of the portfolio and ranks #4213 among its holdings. This is a return to the name: Wealth Enhancement Advisory Services previously reported a position in NMRA as recently as Q3 2025.

Wealth Enhancement Advisory Services first reported a position in NMRA in Q1 2024 and has held it in 5 quarters since. The position peaked at $173K in Q1 2024. 6 funds tracked by Wall St. Rank hold NMRA as of Q3 2026.

  • Wealth Enhancement Advisory Services held 11,176 shares of Neumora Therapeutics worth $5.36K as of Q3 2026.
  • Neumora Therapeutics was a new Wealth Enhancement Advisory Services position in Q3 2026.
  • Neumora Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #4213 holding.
  • Wealth Enhancement Advisory Services first reported a position in Neumora Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Wealth Enhancement Advisory Services's Neumora Therapeutics position peaked at $173K in Q1 2024.
  • 6 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.